A novel protocol to reduce bleeding associated with alteplase treatment of HVAD pump thrombosis

Int J Artif Organs. 2022 Feb;45(2):231-234. doi: 10.1177/0391398821995499. Epub 2021 Feb 18.

Abstract

Pump thrombosis remains a feared complication for patients implanted with durable left ventricular assist devices. Optimal treatment is unknown, but consists of either pharmacologic fibrinolysis or surgical pump exchange. Fibrinolysis is less invasive, but carries a significant risk of intracerebral hemorrhage. We present four cases of LVAD pump thrombosis successfully treated with a novel protocol that consists of low-dose four-factor prothrombin complex concentrate to reverse baseline INR elevation prior to alteplase administration to minimize the risk for intracerebral hemorrhage.

Keywords: Cardiac assist and artificial heart; fibrinolysis; intracerebral hemorrhage; left ventricular assist device; pump thrombosis.

MeSH terms

  • Heart Failure* / drug therapy
  • Heart-Assist Devices* / adverse effects
  • Humans
  • Retrospective Studies
  • Thrombosis* / drug therapy
  • Tissue Plasminogen Activator / adverse effects

Substances

  • Tissue Plasminogen Activator